Healios K.K Future Growth
Future criteria checks 2/6
Healios K.K is forecast to grow earnings and revenue by 35.2% and 40.4% per annum respectively. EPS is expected to grow by 38.2% per annum. Return on equity is forecast to be -240.9% in 3 years.
Key information
35.2%
Earnings growth rate
38.2%
EPS growth rate
| Biotechs earnings growth | 28.4% |
| Revenue growth rate | 40.4% |
| Future return on equity | -240.9% |
| Analyst coverage | Low |
| Last updated | 13 Nov 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 2,408 | -2,763 | -2,369 | -402 | 3 |
| 12/31/2025 | 1,595 | -2,777 | -2,412 | -902 | 3 |
| 12/31/2024 | 905 | -3,289 | -1,428 | -187 | 2 |
| 6/30/2024 | 521 | -5,389 | -3,060 | -2,755 | N/A |
| 3/31/2024 | 124 | -5,515 | -2,790 | -2,759 | N/A |
| 12/31/2023 | 121 | -3,823 | -2,850 | -2,822 | N/A |
| 9/30/2023 | 174 | -3,305 | -2,507 | -2,464 | N/A |
| 6/30/2023 | 176 | -3,301 | -3,294 | -3,198 | N/A |
| 3/31/2023 | 86 | -4,441 | -4,051 | -3,914 | N/A |
| 12/31/2022 | 90 | -5,169 | -4,863 | -4,601 | N/A |
| 9/30/2022 | 41 | -5,172 | -5,955 | -5,691 | N/A |
| 6/30/2022 | 43 | -6,278 | -5,745 | -5,478 | N/A |
| 3/31/2022 | 43 | -5,341 | -5,497 | -5,144 | N/A |
| 12/31/2021 | 41 | -4,910 | -5,389 | -5,089 | N/A |
| 9/30/2021 | 36 | -5,192 | -4,899 | -4,539 | N/A |
| 6/30/2021 | 33 | -4,796 | -4,655 | -4,255 | N/A |
| 3/31/2021 | 29 | -5,278 | -4,751 | -4,392 | N/A |
| 12/31/2020 | 27 | -5,512 | -4,258 | -3,945 | N/A |
| 12/31/2014 | 279 | -480 | N/A | N/A | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: HLOS.F is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: HLOS.F is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: HLOS.F is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: HLOS.F's revenue (40.4% per year) is forecast to grow faster than the US market (9% per year).
High Growth Revenue: HLOS.F's revenue (40.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: HLOS.F is forecast to be unprofitable in 3 years.